Human and porcine smooth muscle cells share similar proliferation dependence on the mevalonate pathway: Implication for in vivo interventions in the porcine model

European Journal of Clinical Investigation

Volumn 26, Issue 11, 1996, Pages 1023-1032

  Martinez Gonzalez J ^a   Badimon, Lina ^a,b  

^a CSIC   (Spain)

^b HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

Author keywords

HMG CoA reductase inhibitors; Porcine model; Restenosis; Smooth muscle cell

Indexed keywords

COMPACTIN; EPIDERMAL GROWTH FACTOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEVALONIC ACID; MEVINOLIN; PLATELET DERIVED GROWTH FACTOR; PRAVASTATIN; THROMBIN;

ANIMAL CELL; ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; CORONARY ARTERY ATHEROSCLEROSIS; CORONARY ARTERY OBSTRUCTION; DNA SYNTHESIS; DRUG EFFECT; HUMAN; HUMAN CELL; NONHUMAN; PRIORITY JOURNAL; RESTENOSIS; SMOOTH MUSCLE FIBER;

EID: 0029902939     PISSN: 00142972     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2362.1996.2550586.x     Document Type: Article

References (64)

1. LaRosa LC, Hunninghake D, Bush D et al. The cholesterol facts. A summary of the evidence relating dietary fats, serum cholesterol, and coronary heart disease. A join statement by the American Heart Association and the National Heart, Lung, and Blood Institute. The Task Force on Cholesterol Issues, American Heart Association. Circulation 1990;81:1721-33.
2. Grundy SM. HMG-CoA reductase inhibitors for treatment of hypercholesterolemia. New Engl J Med 1988;319:24-32.
3. Goldstein JL, Brown MS. Regulation of mevalonate pathway. Nature 1990;343:425-30.
4. Tobert JA. New developments in lipid-lowering therapy: the role of inhibitors of hydroxymethylglutaryl-co-enzyme A reductase. Circulation 1987;76:534-8.
5. Brown G, Albers JJ, Fisher LD et al. Regression of coronary artery desease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B. New Engl J Med 1990;323:1289-98.
6. MAAS Investigators. Effect of simvastatin on coronary atheroma: the Multicenter Anti-Atheroma Study (MAAS). Lancet 1994;344:633-8.
7. Blankenhorn DH, Azen SP, Kramsch DM et al. and the MARS Research Group. The Monitored Atherosclerosis Regression Study (MARS): coronary angiographic changes with lovastatin therapy. Ann Intern Med 1993;119:969-76.
8. Waters D, Higginson L, Gladstone P et al. and the CCAIT Study Group. Effect of monotherapy with an HMG-CoA reductase inhibitor on the progression of coronary artheriosclerosis as assessed by serial quantitative arteriography: the Canadian Coronary Atherosclerosis Intervention Trial. Circulation 1994;89:959-68.
9. Jukema JW, Bruschke AVG, van Boven AJ et al. Effects of lipid lowering by pravastatin on progression and regression of coronary artery disease in symptomatic men with normal to moderately elevated serum cholesterol levels. The Regression Growth Evaluation Statin Study (REGRESS). Circulation 1995;91:2528-40.
10. Group SSSS. Randomised trial of cholesterol lowering in 4444 patiens with coronary heart disease: Scandinavian Simvastatin Survival Study (4S). Lancet 1994;344:1383-9.
11. Furberg CD, Byington RP, Crouse JR, Espeland MA. Pravastatin, lipids and major coronary events. Am J Cardiol 1994;73: 1133-4.
12. Shepherd J, Cobbe SM, Ford I et al. Prevention of coronany heart disease with pravastatin in men with hypercholesterolemia. New Engl J Med 1995;33:1301-7.
13. Cults JL, Bankhurst AD. Suppression of limphoid cell function in vitro by inhibition of 3-hydroxy-3-methylglutaryl coenzyme A reductase by lovastatin. Int J Immunopharmacol 1989;11:863-9.
14. O'Donnell MP, Kasiske BL, Kim Y, Atluru D, Keane WF. Lovastatin inhibits proliferation of rat mesangial cells. J Clin Invest 1993;91:83-7.
15. Mallat A, Preaux A-M, Blazejewski S, Dhumeaux D, Rosenbaum J, Mavier P. Effect of simvastatin, an inhibitor of hydroxy-methylglutaryl coenzyme A reductase, on the growth of human Ito cells. Hepatology 1994;20:1589-94.
16. 2+ influx induced by IGF-I in FRTL-5 cells. Biochem Biophys Res Com 1991;177:17-21.
17. Jakóbisiak M, Bruno S, Skiersky JS, Darzynkiewicz Z. Cell cycle-specific effects of lovastatin. Proc Natl Acad Sci USA 1991;88:3628-32.
18. Falke P, Mattiasson I, Stavenow L, Hood B. Effects of a competitive inhibitor (mevinolin) of 3-hydroxy-3-methylglutaryl coenzyme A reductase on human and bovine endothelial cells, fibroblasts and smooth muscle cells in vitro. Pharmacol Toxicol 1989;64:173-6.
19. Corsini A, Mazzoti M, Raiteri M et al. Relationship between mevalonate pathway and arterial myocyte proliferation: in vitro studies with inhibitors of HMG-CoA reductase. Atherosclerosis 1993;101:117-25.
20. Goldstein JL, Basu SK, Brown MS. Receptor-mediated endocytosis of low-density lipoprotein in cultured cells. Methods Enzymol 1983;98:241-60.
21. Quesney-Huneeus V, Galick HA, Siperstein MD, Erickson SK, Spencer TA Nelson JA. The dual role of mevalonate in the cell cycle. J Biol Chem 1983;258:378-85.
22. Siperstein MD. Role of cholesterogenesis and isoprenoid synthesis in DNA replication and cell growth. J Lipid Res 1984; 25:1462-8.
23. Fuster V, Badimon L, Badimon JJ, Chesebro JH. The pathogenesis of coronary artery disease and acute coronary syndromes (Part I). New Engl J Med 1992;326:242-50.
24. Fuster V, Badimon L, Badimon JJ, Chesebro JH. The pathogenesis of coronary artery disease and acute coronary syndromes (Part II). New Engl J Med 1992;326:310-18.
25. Badimon JJ. Fuster V, Chesebro JH, Badimon L. Coronary atherosclerosis: a multifactorial disease. Circulation 1993;87: II-3 II-6.
26. Gellman J, Ezekowitz MD, Sarembock IJ et al. Effect of lovastatin on intimal hyperplasia after balloon angioplasty: a study in an atherosclerotic hypecholesterolemic rabbit. J Am Coll Cardiol 1991;17:251-9.
27. Soma MR, Donetti E, Parolini C et al. HMG-CoA reductase inhibitors. In vivo effects on carotid intimal thickening in normocholesterolemic rabbits. Arterioscler Thromb 1993;13:571-8.
28. Schneider JE, Santoian EC, Gravanis MB, Cipolla G, Anderberg K, King SB. Lovastatin fails to limit smooth muscle cell proliferation in normolipemic and hyperlipemic swine in an overstretch balloon injury model of restenosis (abstract). J Am Coll Cardiol 1992;19(suppl.)163A.
29. Weintraub WS, Boccuzzi SJ, Klein JL et al. Lack of effect of lovastatin on restenosis after coronary angiplasty. New Engl J Med 1994;331:1331-7.
30. Ross R. The smooth muscle cell. II. Growth of smooth muscle in culture and formation of elastic fibers. J Cell Biol 1971;50:172-86.
31. Varela O, Royo T, Badimon L. Agonist-induced platelet secretion and coronary smooth muscle cell proliferation. Eur J Clin Invest 1994;24(suppl. 2):59A.
32. Skalli O, Ropraz P, Trezciak A, Benzonana G, Gillessen D, Gabbiani G. A monoclonal antibody against alfa-smooth muscle actin: a new probe for smooth muscle differentiation. J Cell Biol 1986;103:2787-96.
33. Naiem M, Gerdes J, Abdulaziz Z et al. The value of immunohistological screening in the production of monoclonal antibodies. J Immunol Methods 1982;50:145-60.
34. Singer KH, Scearce RM, Tuck DT, Whichard LP, Denning SM, Haynes BF, Removal of fibroblasts from human epithelial cell cultures with use of a complement fixing monoclonal antibody reactive human fibroblasts and monocytes/macrophages. J Invest Dermatol 1989;92:166-70.
35. Havel RJ, Eder HA, Bragdon JH. The distribution and chemical composition of ultracentrifugally separated lipoproteins in human serum. J Clin Invest 1955;34:1345-53.
36. Laemmli UK. Cleavage of structural proteins during the assembly of the head of the bactheriophage T4. Nature 1970;227:680-5.
37. Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biol Chem 1976;72:248-54.
38. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. Protein measurement with the Folin phenol reagent. J Biol Chem 1951;193:265-75.
39. Hohl RJ, Larson RA, Mannickarottu V, Yachnin S. Inhibition of hydroxymethylglularyl coenzyme A reductase activity induces a paradoxical increase in DNA synthesis in myeloid leukemia cells. Blood 1991;77:1064-1070.
40. Traganos F, Darzynkiewicz Z, Melamed MR. The ratio of RNA to total nucleic content as a quantitative measure of unbalanced cell growth. Cytometry 1982;21:212-18.
41. Oka Y, Orth DN. Human plasma epidermal growth factor/betauragastrone is associated with blood platelets. J din Invest 1983;72:249-59.
42. Ross R, Vogel A. The platelet-derived growth factor. Cell 1978;14:203-10.
43. Vu TK, Hung DT, Wheaton VI, Coughlin SR. Molecular cloning of a functional receptor reveals a novel proteolytic mechanism of receptor activation. Cell 1991;64:1057-1068.
44. 2+ mobilization. FEBS Lett 1991;288:123-8.
45. Maltese WA. Posttranslational modifications of proteins by isoprenoids in mammalian cells. FASEB J 1990;4:3319-28.
46. Cuthbert JA, Lipsky PE. Suppression of the proliferation of rastransformed cells by fluoromevalonate, an inhibitor of mevalonate metabolism. Cancer Res 1995;55:1732-40.
47. Corsini A, Raiteri M, Soma MR, Bernini F, Fumagalli R, Paoletti R. Pathogenesis of atherosclerosis and the role of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors. Am J Cardiol 1995;76:21A-28A.
48. Corsini A, Raiteri M, Soma MR, Fumagallis A, Paoletti A. Simvastatin but not pravastatin inhibits the proliferation of rat aorta myocytes. Pharm Res 1991;23:173-180.
49. Serizawa N, Serizawa K, Nakagawa K, Furuya T, Okazaki T, Terahara A. Microbial hydroxylation of ML-236B (compactin). Studies on microorganisms capable of 3b-hydrozylation of ML-236B. J Antibiotics 1983;36:887-91.
50. Alberts AW, Chen J, Kuron G et al. Mevinolin: a highly potent competitive inhibitor of HMG-CoA reductase and a cholesterol-lowering agent. Proc Natl Acad Sci USA 1980;77:3957-61.
51. Endo A, Kuroda M, Tsujita Y. ML-236A, MI-236B and ML-236C, new inhibitors of cholesterogenesis produced by Penicillium citricum. J Antibiot 1976;29:1346-8.
52. Tsujita Y, Kuroda M, Shimada Y et al. CS-514, a competitive inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase: tissue-selective inhibitor of sterol synthesis and hypolipidemic effect on various animal species. Biochem Biophys Acta 1986; 877:50-60.
53. Scott WA, Mahoney EM, Mosley ST. Mechanism of action and differential pharmacology of pravastatin, a hydrophilic and selective HMG-CoA-reductase inhibitor. In: LaRosa JC, ed. New Advances in the Control of Lipid Metabolism: Focus on Pravastatin, International Congress and Symposium Series. London, Royal Society of Medicine Services, 1989: 1 8.
54. Van Vliet AK, van Thiel GCF, Huisman RH, Moshage H, Yap SH, Cohen LH. Different effects of 3-hydroxy-3-methylglutarylcoenzyme A reductase inhibitors on sterol synthesis in various human cell types. Biochim Biophys Acta 1995;1254:105-11.
55. Quesney-Hunecus V, Wiley MH, Siperstein MD. Essential role for mevalonate synthesis in DNA replication. Proc Natl Acad Sci USA 1979;76:5056-60.
56. Pan HY, DeVault AR, Wang-Iverson D, Ivashkiv E, Swanson BN, Sugarmann AA. Comparative pharmacokinetics and pharmacodynamics of pravastatin and lovastatin. J Clin Pharmacol 1990;30:1128-35.
57. Stubbs RJ, Schwartz MS, Gerson RJ, Thornton TJ, Bayne WF. Comparison of plasma profiles lovastatin (mevinolin), simvastatin (epistatin) and pravastalin (eptastatin) in the dog. Drug Invest 1990;2:18-28.
58. Pan HY, DeVault AR, Swites BJ et al. Pharmacokinetics and pharmacodynamics of pravastatin alone and with cholestyramine in hypercholesterolemia. Clin Pharmacol Ther 1990b; 48:201-7.
59. Welling PG. Pharmacokinetics: Processes and Mathematics. Washington: American Chemical Society, 1986: 77-102.
60. Fernández-Ortiz A, Budimon JJ, Falk E et al. Characterization of the relative thrombogenicity of atherosclerotic plaque components: implications for consequences of plaque rupture. J Am Coll Cardiol 1994;23:1562-9.
61. Fernández-Ortiz A, Meyer BL, Mailhac A et al. A new approach for local intravascular drug delivery: iontophoretic balloon. Circulation 1994;89:1518-22.
62. Ip JH, Fuster V, Badimon L, Badimon JJ, Taubman MB, Chesebro JH. Syndromes of accelerated atherosclerosis: role of vascular injury and smooth muscle cell proliferation. J Am Coll Cardiol 1990;15:1667-87.
63. Meyer BJ, Fernández-Ortiz A, Mailhac A et al. Local delivery of r-hirudin by double balloon perfusion catheter prevents mural thrombosis and minimizes platelet deposition after angioplasty. Circulation 1994;90:2474-80.
64. Soma MR, Parolini C, Donetti E, Fumagalli R, Paoletti R. Inhibition of isoprenoid biosynthesis and arterial smooth-muscle cell proliferation. J Cardiovasc Pharmacol 1995;25(suppl 4):S20-S24.